Log in or Sign up for Free to view tailored content for your specialty!
Bone Marrow Transplantation News
Maintenance lenalidomide after allogeneic HSCT improved response in high-risk multiple myeloma
Maintenance lenalidomide after allogeneic hematopoietic stem cell transplantation was associated with greater overall response but increased acute graft-versus-host disease among patients with high-risk multiple myeloma, according to study results.
FDA grants fast track designation to PRM-151 for myelofibrosis
The FDA granted fast track designation to PRM-151 as a potential treatment for patients with myelofibrosis, the drug’s manufacturer announced.
Log in or Sign up for Free to view tailored content for your specialty!
Efforts intensify to ensure accessibility, sustainability of HSCT
Hematopoietic stem-cell transplant, initially developed as a rescue therapy for patients with cancer, has evolved over the past few decades into a standard treatment for many patients with benign and malignant hematologic conditions.
Double-unit cord-blood transplant failed to extend survival in blood cancers
Children and adolescents with hematologic malignancies who underwent double-unit cord-blood transplantation experienced similar survival rates as those who underwent single-unit transplants, according to results of a phase 3 randomized trial.
FDA grants orphan drug status to Glassia for GVHD
The FDA granted orphan drug designation to a liquid alpha-1 proteinase inhibitor for the treatment of patients with graft-versus-host disease following allogeneic bone marrow stem cell transplant, its manufacturer announced recently.
GVHD prophylaxis with single-agent cyclophosphamide effective after allogeneic transplant
Post-transplant graft-versus-host disease prophylaxis with single-agent cyclophosphamide appeared safe and effective in patients who underwent conditioning with busulfan and fludarabine prior to allogeneic bone marrow transplantation, according to results of a multi-institutional study.
Cancer center names BMT director
William Tse, MD, has been named director of bone marrow transplantation at the University of Louisville James Graham Brown Cancer Center.
Cancer center names director of BMT
William Tse, MD, has been named director of bone marrow transplantation at the University of Louisville James Graham Brown Cancer Center.
HLA-matched donors available for most HSCT candidates
A majority of hematopoietic stem-cell transplantation candidates who do not have related donors have suitable adult donors or cord-blood units through the National Marrow Donor Program’s registry, according to results of a modeling study.
Somatic mutations in myelodysplastic syndrome linked to shorter survival after HSCT
Patients with myelodysplastic syndrome who harbored TP53, TET2 or DNMT3A mutations demonstrated significantly shorter OS after allogeneic hematopoietic stem-cell transplantation, according to study results.